The latest chart-based Vaxart stock price forecast places emphasis on MACD turning positive, a rare occurrence amid recent downtrends, often signaling incoming momentum bursts. Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We have appealed Nasdaq’s suspension and are scheduled to meet with their hearings panel on August 14, 2025. But based on our discussions and the realities of the market, we believe relisting is contingent on conducting a reverse stock split. Vaxart’s share price forecast often reflects FDA-related news cycles. With small-cap biotech ETFs showing a mild uptrend this month, any positive trial data could push VXRT above $0.80, though downside to $0.58 remains possible on delays.